



A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours

Silke Gillessen^{a,3}, Ulrike S. Gnad-Vogt^{b,1,3}, Elisa Gallerani^c, Joachim Beck^d,
Cristiana Sessa^c, Aurelius Omlin^a, Maria R. Mattiacci^{e,2}, Bernd Liedert^b,
Daniel Kramer^f, Julien Laurent^{b,g}, Daniel E. Speiser^h, Roger Stupp^{g,*}

^a Kantonsspital, St. Gallen, Switzerland

^b Merck KGaA, Darmstadt, Germany

^c Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

^d University of Mainz, Mainz, Germany

^e Merck Serono SA – Geneva, Geneva, Switzerland[†]

^f Merck Serono Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany

^g University of Lausanne Hospitals (CHUV), Lausanne, Switzerland

^h Ludwig Center for Cancer Research, Lausanne, Switzerland

Available online 20 August 2012

KEYWORDS

Phase I
Selectikine
EMD 521873
Dose-escalation
Advanced solid tumours

Abstract Background: EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study.

Methods: Patients had metastatic or locally advanced solid tumours failing previous standard therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days, every 3 weeks. A subgroup of patients also received 300 mg/m² cyclophosphamide on day 1 of each cycle. Escalating doses of Selectikine were investigated with the primary objective of determining the maximum tolerated dose (MTD).

Results: Thirty-nine patients were treated with Selectikine alone at dose levels from 0.075 to 0.9 mg/kg, and nine were treated at doses of 0.45 and 0.6 mg/kg in combination with cyclophosphamide. A dose-dependent linear increase of peak serum concentrations and area under curve was found. The dose-limiting toxicity was grade 3 skin rash at the 0.9 mg/kg dose-level; the MTD was 0.6 mg/kg. Rash and flu-like symptoms were the most frequent side-effects. No

* Corresponding author. Address: University of Lausanne Hospitals (CHUV), 46, rue du Bugnon, Lausanne 1011, Switzerland. Tel.: +41 21 314 0156; fax: +41 21 314 0737.

E-mail address: Roger.Stupp@chuv.ch (R. Stupp).

¹ Current address: CureVac GmbH, Frankfurt, Germany.

² Current address: Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.

³ These authors contributed equally to this manuscript.

⁴ A branch of Merck Serono SA, Coinsins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.

severe cardiovascular side-effects (hypotension or vascular leak) were observed. At all dose-levels, transient increases in total lymphocyte, eosinophil and monocyte counts were recorded. No objective tumour responses, but long periods of disease stabilisation were observed. Transient and non-neutralising Selectikine antibodies were detected in 69% of patients.

Conclusions: The MTD of Selectikine with or without cyclophosphamide administered under this schedule was 0.6 mg/kg. The recommended phase II dose was 0.45–0.6 mg/kg. Selectikine had a favourable safety profile and induced biological effects typical for IL-2.

© 2012 Elsevier Ltd. Open access under [CC BY-NC-ND license](#).

1. Introduction

Immunocytokines comprise a monoclonal antibody fused to a cytokine. Targeting tumour antigens via the antibody moiety facilitates cytokine enrichment in the local tumour microenvironment, achieving the concentrations required to induce an effective immune response.¹ In murine cancer models, interleukin-2 (IL-2)-containing immunocytokines demonstrated superior dose-dependent antitumour activity compared with equimolar doses of the free cytokine and antibody.^{2–4}

IL-2 demonstrates antitumour activity,^{5–7} and was the first cytokine to be fused to tumour-targeting antibodies, but similar to free recombinant IL-2, severe hypotension and vascular leak syndrome remained dose-limiting when immunocytokines were tested in patients with advanced solid tumours.^{8–11} EMD 521873 or NHS-IL2LT (Selectikine, Merck KGaA, Darmstadt, Germany) is a novel immunocytokine comprising genetically modified IL-2 with decreased vascular toxicity fused with a DNA-targeting antibody moiety, NHS76.

NHS76, a fully human de-immunised monoclonal antibody,¹² binds free DNA fragments without requirements for specific nucleotide sequences or recognised secondary structures (Merck KGaA data on file). DNA is often released from dying tumour cells, either spontaneously, or during their exposure to radiation or chemotherapy.^{13–16} Systemic or intra-tumoural administration of TNT1, (iodine131 radio-labelled precursor of NHS76) successfully targeted different tumour types.^{17–20}

Selectikine acts predominantly on activated T-cells via the high-affinity IL-2 receptor, and shows minimal activity for the intermediate-affinity receptor, a suspected mediator of vascular toxicity mainly expressed by NK cells.²¹ Genetic modification of the fusion junction (M1) of Selectikine has increased its serum half-life.²²

In preclinical studies, CD8-dependent Selectikine antitumour activity was shown in murine tumour models.²¹ Intermittent dosing every three weeks in cynomolgus monkeys was well tolerated, without the induction of cardiovascular side-effects.¹⁸ Mild to moderate side-effects were observed including typical IL-2-target organ toxicity and a transient increase in lymphocyte subpop-

ulations.²¹ Selectikine generally demonstrated a better safety profile than other immunocytokines containing unmodified IL-2 (Merck KGaA, data on file).

This first-in-man phase I clinical trial investigated the safety and tolerability of Selectikine in patients with refractory, advanced solid tumours. IL-2 treatment induces an increase in regulatory T-cells, which express the high-affinity IL-2 receptor and can also be activated by Selectikine. Low-dose cyclophosphamide might potentiate the antitumour activity of immunotherapies via depletion of regulatory T-cells,^{23–26} and was associated with increased lymphokine-activated killer cells in IL-2 treated melanoma patients.²⁷ Combining low-dose cyclophosphamide with Selectikine was explored in this trial to investigate if the anticipated effect of Selectikine on regulatory T-cells could be limited.

2. Materials and methods

2.1. Study design

This open-label, multicentre phase I study aimed to determine the Selectikine maximally tolerated dose (MTD) administered alone (group 1) or with low-dose cyclophosphamide (group 2). Secondary objectives were to evaluate pharmacokinetics (PK), immunogenicity, biological and clinical response, progression-free survival (PFS) and overall survival (OS). The regimen was selected based on preclinical data and prior clinical experience with other immunocytokines containing unmodified IL-2.^{8–10,21,28}

The study was performed with local ethics committee and regulatory authority approval and in accordance with the declaration of Helsinki and the International Conference on Harmonization.

2.2. Main patient eligibility criteria

All patients gave written informed consent. Eligible patients were ≥ 18 years, with Eastern Cooperative Oncology Group performance status of ≤ 1 , adequate organ function, histologically/cytologically proven solid tumours or B-cell non-Hodgkin's lymphoma after failure of standard therapy. Patients requiring treatment with immunosuppressive agents, or having autoimmune disease, inflammatory bowel disease, chronic viral infec-

tions or significant cardiovascular or pulmonary disease, were ineligible.

2.3. Treatment

Selectikine, (intravenous [iv] infusion over 1 h) was administered on days 1–3 of a 21-day cycle. Group 2 patients received 300 mg/m² cyclophosphamide (iv infusion over 1 h), 1 day before the first Selectikine dose in each cycle. Treatment continued until tumour progression or the occurrence of intolerable side-effects. Pre- and co-medication included a non-steroidal anti-inflammatory drug to alleviate flu-like symptoms.

2.4. Dose escalation

The starting dose of 0.075 mg/kg Selectikine was chosen after preclinical evaluation (Merck KGaA data on file). Rapid dose-escalation was planned if no relevant \geq grade 2 toxicity was observed with two single-patient cohorts. Otherwise, three-patient cohorts were treated per dose level, with expansion to six-patient cohorts in the presence of dose limiting toxicity (DLT). No inpatient dose-escalation was allowed. Dose-escalation occurred if 0/3 or \leq 1/6 patients experienced DLT, defined as any grade \geq 3 treatment-related adverse events (AEs) occurring in cycle 1. Grade 3 fever and chills lasting <6 h, allergic reactions, grade 3 rash improving to grade 2 in <24 h, grade 3 nausea and vomiting improving with antiemetic treatment, and specified laboratory abnormalities were not considered DLTs. Patients receiving at least one Selectikine dose were evaluable for DLTs. Patients not experiencing DLTs should have received the full scheduled doses in cycle 1 to be included in the DLT analysis, patients discontinuing early for reasons other than toxicity were replaced.

The MTD was the highest dose in cycle 1 in which there were no DLTs/3 patients or \leq 1 DLT/6 patients. Following MTD determination, additional patients were enrolled (group 1a) at dose levels below the MTD to obtain further information on changes in biological parameters.

2.5. Clinical assessments

Assessments were performed on days 1, 3, 4 and 8, and at the end of study visit 28 days after the last dose Selectikine. Vital signs were recorded at the start of infusion, every 15 min until the end of the infusion (EOI), then every 30 min until 2 h after EOI and then hourly until 6 h after EOI. AEs were graded by the National Cancer Institute (NCI) common criteria for AEs (version 3.0). Tumour response was assessed every 6 weeks according to RECIST²⁹ and patients were followed until death or for \geq 1 year after study closure.

2.6. Pharmacokinetic and pharmacodynamic analysis

Serum Selectikine was analysed by an enzyme-linked immunosorbent assay (ELISA, [Supplemental Material](#)). PK analysis was performed using Kinetica™ (version 4.4.1 2002, Innaphase PA, USA). Patient Selectikine PK parameters were determined on day 1 of cycles 1 and 3 by non-compartmental analysis. Single-dose parameters included: maximum serum concentration (C_{max}), time to reach maximum serum concentration (t_{max}), area under the curve (AUC) from time zero to time of last concentration above lower limit of quantification (AUC_{0-t}), AUC from time zero to infinity ($AUC_{0-\infty}$), and terminal half life ($t_{1/2}$). Accumulation was assessed by comparing the day 1 values for AUC_{0-t} and C_{max} between cycles 1 and 3 and the EOI and pre-infusion concentrations on days 1 and 2 of cycles 1–3. Selectikine dose proportionality was assessed by plotting the dose-dependent parameters C_{max} and AUC_{0-t} as a function of various absolute dose levels administered on day 1 of cycle 1.

2.7. Immunogenicity

Serum Selectikine antibodies were detected using a bridging ELISA ([Supplemental Material](#)).

2.8. Statistical methods

Descriptive statistics were used for baseline characteristics, safety assessments, PK and immunogenicity variables. Survival analyses were performed by the Kaplan–Meier method. Counts of leukocyte subsets were compared between days 1 and 8 of the first two cycles using repeated measurements mixed model analysis of variance (ANOVA). Full statistical analyses are described in the [Supplemental Material](#).

3. Results

3.1. Patient characteristics and MTD determination

Between December 2006 and May 2009, 48 patients were enrolled: 39 were treated with Selectikine alone (group 1) and nine with Selectikine plus cyclophosphamide (group 2) ([Table 1](#)). Thirty-seven patients were evaluable for DLT and 42 for efficacy.

Selectikine dose levels and DLTs are summarised in [Table 2](#). In group 1, two potential DLTs were observed at 0.3 mg/kg, the study was continued at the previous dose level (0.15 mg/kg) with no further DLTs. The protocol was subsequently amended to exclude asymptomatic intermittent laboratory changes as DLTs, and doses were escalated by 50% instead of 100% dose-increments up to 0.9 mg/kg. Four DLTs were reported: one grade 3 dyspnoea (0.3 mg/kg) and three grade 3 skin rash (one

Table 1
Patient and disease characteristics at baseline.

Characteristic	Group 1 (n = 39)	Group 2 (n = 9)
Median age, years (range)	60 (24–76)	52 (31–78)
Sex, n (%)		
Male	22 (56)	3 (33)
Female	17 (44)	6 (67)
ECOG PS, n (%)		
0	29 (74)	7 (78)
1	10 (26)	2 (22)
Tumour type, n (%)		
Colorectal carcinoma	15 (39)	1 (11.1)
Ovarian carcinoma	6 (15)	1 (11.1)
Prostate carcinoma	3 (8)	0
Renal cell carcinoma	4 (10)	0
Skin carcinoma	2 (5)	2 (22.2)
Other	9 ^a (18)	5 ^b (55.5)
Time from metastatic/recurrence diagnosis to study entry, Median, (range in years)	2.39 (0.1–6.2)	2.05 (1.3–8.7)
Previous therapy ^c		
Surgery	35 (90)	7 (78)
Chemotherapy	36 (92)	9 (100)
Radiotherapy	16 (41)	6 (67)
Monoclonal antibody	15 (39)	2 (22)
Hormonal	6 (15)	1 (11)
Immunotherapy	7 (18)	3 (33)
Other	14 (36)	1 (11)

ECOG PS, Eastern Cooperative Oncology Group performance status.

^a One of each: adrenal gland carcinoma; breast carcinoma; hypopharyngeal carcinoma; non small cell lung carcinoma; small cell lung carcinoma; osteosarcoma; pleural mesothelioma; urothelial carcinoma and endometrial carcinoma.

^b One of each: parotid gland carcinoma; synovial sarcoma; tongue carcinoma; thymic carcinoma; nasopharyngeal carcinoma.

^c Excluding palliative radiotherapy and surgery.

Table 2
Selectikine dosing and DLTs.

Dose level (mg/kg)	Number of patients			DLT and grade 3 toxicity ^a
	Group 1 (n = 28)	Group 2 (n = 9)	Group 1a (n = 11)	
0.075	1	0	5	None
0.15	6	0	0	One patient with grade 3 lymphopenia and PTT increase, not clinically relevant (no DLT recorded as per amended protocol)
0.225 ^b	3	0	3	None
0.3	6	0	0	1 DLT; grade 3 dyspnoea without evidence of vascular leak (no oedema or infiltrates on high resolution CT scan), finally assessed as related to tumour progression One patient with grade 3 increase in lipase, not clinically relevant (no DLT recorded as per amended protocol)
0.45 ^b	3	3	3	None
0.6	6	6	0	1 DLT; grade 3 rash in group 1 and 1 DLT; grade 3 rash in group 2
0.9	3	0	0	2 DLTs; grade 3 rash

DLT, dose limiting toxicity; PTT, partial thromboplastin time; CT computed tomography.

^a Grade 3 toxicities after cycle 1 in group 1a only.

^b These doses were included following suspected DLTs at the 0.3 mg/kg dose. Following a protocol amendment to exclude asymptomatic intermittent laboratory changes from DLT, Selectikine dosing was returned to the previous dose level and dose escalation restarted by 50% instead of 100% dose increments.

at 0.6 mg/kg and two at 0.9 mg/kg). The Selectikine MTD was determined as 0.6 mg/kg.

Eleven patients (group 1a) were subsequently enrolled and treated with Selectikine at 0.075, 0.225 and 0.45 mg/kg in a sequential order.

Nine patients were treated in group 2 (Selectikine 0.45 mg/kg and 0.6 mg/kg), one experienced a DLT (grade 3 skin rash at 0.6 mg/kg).

The median number of cycles per patient was 2 (range 1–10). The majority of patients (n = 20) received 2




Fig. 1. Mean (standard deviation) concentration–time profile for Selectikine after the first infusion (day 1) of cycle 1.

2–3 as indicated by mean $\text{trough}_{(\text{day}3)}/\text{trough}_{(\text{day}2)}$ ratios across all dose-levels (1.15, 1.14 and 1.04 for cycles 1, 2 and 3, respectively). The corresponding $C_{\text{max}(\text{day}3)}/C_{\text{max}(\text{day}2)}$ ratios did not reveal significant day-to-day accumulation (0.97, 1.14 and 1.03 for cycles 1, 2 and 3, respectively). Predose concentrations on day 1 of cycle 3 were mainly below the LLOQ, suggesting no measurable accumulation from the previous cycle. Nevertheless a 1.3–1.9 fold increase for C_{max} and a 1.8–2.6 increase for AUC_{0-t} were observed in cycle 3, when compared to cycle 1. The $t_{1/2}$ ranged between 7.8 and 11 h in cycle 1 and between 9.5 and 18 h in cycle 3 in both groups. Pre-treatment with cyclophosphamide may result in a slight decrease in exposure to Selectikine, but this was not statistically significant.

3.4. Immunogenicity

Serum Selectikine antibodies were detected in 33/48 patients (69%), with peaks occurring on day 8 of cycle 1 in the majority. A decline in antibody detection with subsequent administrations suggested a transient immune response against Selectikine. Antibodies did not appear to be neutralising as they influenced neither the PK nor the biological activity of Selectikine. Increases in total lymphocytes, CD4+, CD8+ and NK cells in cycles 1 and 2 were not reduced by the presence of Selectikine antibodies (data not shown).

3.5. Antitumour activity

No tumour responses were recorded, however SD for >6 weeks was noted in 12/48 (25%) patients. Median survival time was 9.6 months (95% CI 5.6–16.4) in group 1 and 7.0 months (95% CI 4.3–23.2) in group 2.

Selectikine treatment was associated with a potential clinical benefit in four patients, one patient with refractory recurrent small cell lung cancer (stable for >10

months), two patients with colorectal cancer and one patient with ovarian cancer (Supplemental Material).

4. Discussion

In this first-in-human phase I study, Selectikine treatment was associated with typical IL-2-like biological effects including lymphopenia followed by lymphocytosis and eosinophilia at all dose levels, while IL-2 related clinical AEs were mainly mild to moderate. DLT was skin rash, which responded well to topical corticosteroids.

In previous studies with intermediate to high IL-2 doses, or with other IL-2-based immunocytokines, vascular leak syndrome and hypotension were common side-effects, thought to be due to activation of the intermediate-affinity IL-2 receptor and direct activation of endothelial cells.^{8–10} In contrast, Selectikine induced only mild hypotension and no vascular leak syndrome demonstrating improved cardiovascular tolerability of the modified and more selective IL-2 moiety.

Following administration, Selectikine PK appeared to be linear. The increased exposure and prolonged Selectikine half-life in cycle 3 was surprising; predose levels measured at day 1 were below LLOQ and no identifiable changes in physiological factors, which might have impacted on clearance rate or volume of distribution were found. While the reported dose–exposure relationship for Selectikine was similar to that observed for other structurally related fusion proteins, the Selectikine half-life was notably longer than that reported for other IL-2 immunocytokines or unmodified recombinant IL-2.^{8,9,28} This comparatively longer half-life can be attributed to the lysine to alanine amino acid substitution in the junction sequence between antibody and IL-2 component. This effect is assumed to be independent of binding to either Fc γ receptors or the Fc protection receptor, but was associated with changes in susceptibility to intracellular proteases.²²

Table 4

Main pharmacokinetic (PK) parameters of serum Selectikine obtained on day1 following first infusion cycle 1 and cycle 3.^a

Parameter ^a	Treatment groups/cycle/dose (mg/kg)													
	Group 1/cycle 1							Group 1/ cycle 3				Group 2/cycle 1		Group 2/cycle 3
	0.075 (n = 6)	0.15 (n = 6)	0.225 (n = 6)	0.3 (n = 6)	0.45 (n = 6)	0.6 (n = 6)	0.9 (n = 6)	0.075 (n = 3)	0.15 (n = 3)	0.3 (n = 1)	0.6 (n = 1)	0.45 (n = 3)	0.6 (n = 6)	0.6 (n = 1)
Dose, mg														
Mean	5.2	12.4	16.4	23.4	30.9	38.2	73.2	5.6	10.3	30	27.6	28.4	43.3	35.0
Co-efficient of variation (CV) %	33.7	14.3	20.9	15.5	24.2	21.1	3.9	34.9	19.3			9.3	15.6	
Range	2.9–7.6	9.8–14.3	13.0–21.4	19.7–30.0	20.0–39.6	27.6–49.0	70.0–75.6	3.6–7.5	8.6–12.5			26.1–31.3	33.0–50.0	
C _{max} , µg/mL														
Mean	1.1	2.7	3.7	4.7	8.2	7.8	10.5	1.8	3.1	8.6	11.4	6.2	7.4	7.6
CV%	46.0	26.2	18.0	21.7	34.7	30.5	18.5	32.5	17.8			21.3	42.1	
Range	0.5–1.8	2.0–4.2	2.9–4.6	3.5–6.3	6.0–12.7	5.4–10.7	8.5–11.8	1.5–2.6	2.6–3.6			5.2–7.8	4.3–12.1	
t _{max} , hrs														
Median	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	2.0	1.0	1.0	1.0
Range	1.0–2.0	1.0–1.1	1.0–1.4	1.0–2.0	1.0–1.1	1.0–2.0	0.5–1.0	1.0–1.1	1.0–1.1			1.0–1.0	1.0–1.0	
AUC _{0-t} µg/mL ^a h														
Mean	7.9	24.0	30.1	39.0	55.0	57.8	83.3	15.5	40.8	110.9	153.4	44.8	46.6	84.1
CV%	67.9	22.9	9.2	17.1	28.5	24.8	29.1	92.0	28.9			20.4	31.8	
Range	2.9–5.9	16.9–32.2	26.6–33.6	30.1–47.1	33.5–73.9	39.0–69.9	63.8–112.5	6.5–29.9	29.5–50.0			37.0–55.3	33.6–78.4	
AUC _{0-∞} µg/mL ^a h														
Mean	12.0	29.0	35.2	47.7	68.6	70.0	106.3	21.6	60.3	171.4	249.5	52.5	56.2	115.9
CV%	52.3	25.1	11.5	16.2	33.1	21.2	27.2	104	44.4			20.3	35.2	
Range	5.0–19.8	18.9–39.7	29.8–39.5	36.1–55.7	40.3–105.1	47.7–81.7	89.4–144.5	8.4–44.5	37.2–82.0			43.8–65.2	39.4–94.4	
t _{1/2} , hrs														
Mean	7.8	9.3	8.3	9.9	10.0	9.5	11.1	9.5	14.0	15.5	17.7	8.7	10.1	12.5
CV%	31.2	19.0	12.6	12.7	29.2	17.3	26.5	72.7	27.9			4.8	19.8	
Range	5.2–11.9	7.2–12.3	6.6–9.7	8.6–11.6	7.5–15.5	8.0–12.7	8.6–14.4	4.5–14.5	10.2–16.9			8.4–9.2	8.4–14.5	

AUC_{0-t}, area under the serum concentration–time curve from time zero to the time of the last concentration above the lower limit of quantification; AUC_{0-∞}, area under the serum concentration–time curve from time zero to infinity; C_{max}, maximum observed serum concentration; CV, co-efficient of variation; t_{1/2}, terminal half life; t_{max}, time to reach maximum serum concentration.

^a Means are geometric means, apart from means for dose.




Fig. 2. Dose proportionality of PK parameters for group 1 during cycle 1. (A) C_{max} , (B) AUC_{0-t} and (C) $AUC_{0-\infty}$. C_{max} , maximum observed serum concentration; AUC_{0-t} , area under the serum concentration–time curve from time zero to the time of the last concentration above the lower limit of quantification; $AUC_{0-\infty}$, area under the serum concentration–time curve from time zero to infinity.

A transient clinically irrelevant immunogenic effect was observed in the majority of patients (69%). Antibody responses were also observed after treatment with other IL-2-immunocytokines.^{8–10} Interestingly, preliminary immunogenicity data from a phase I trial with L19-IL-2, consisting of the recombinant human anti-

body fragment L19 (highly specific for the extra domain B of fibronectin), fused with unmodified human IL-2 indicate a very low immunogenic potential.⁹

Antitumour activity was reported in this heterogeneous and heavily pretreated patient population as prolonged disease stabilisation and a transient drop in

tumour markers. Combination or intercalation of immunocytokine treatment with chemotherapy or radiation may facilitate the generation of an effective antitumour immune response by increased tumour antigen release, and activation of dendritic cells and tumour antigen specific T-cells.³⁰ Also IL-2 containing immunocytokines may be clinically more effective if administered in patients with less tumour burden or non-bulky tumour disease. In a phase II study in children with refractory neuroblastoma, whereas no responses were observed in children with bulky metastatic disease, complete responses occurred in 5/23 (21.7%) children with low disease burden.³¹

The data indicate that low-dose cyclophosphamide can be safely combined with Selectikine without the need for dose reductions of the immunocytokine. While the PK was not appreciably modified, the number of patients treated with cyclophosphamide is too low to draw reliable conclusions. Detailed analyses of a potential effect on immune responses are ongoing.

In conclusion, compared with historical data reporting IL-2 treatment, improved cardiovascular tolerance and an overall favourable safety profile were demonstrated for Selectikine, a novel immunocytokine with selective IL-2 activity targeting free DNA. DLT was skin rash and a dose of 0.45–0.6 mg/kg was recommended for further phase II evaluation. Further trials of this compound in combination with standard chemotherapy and radiotherapy or in patients with limited tumour burden are warranted.

Conflict of interest statement

Julien Laurent and Bernd Liedert are employees of Merck KGaA, Darmstadt, Germany. Maria Mattiaci was an employee of Merck Serono S.A. – Geneva, Geneva, Switzerland, a branch of Merck Serono SA, Coin-sins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, until June 2011. Daniel Kramer an employee of Merck-Serono, Grafing, Germany. Ulrike Gnad-Vogt was an employee of Merck KGaA, Darmstadt, Germany from 2005 to 2008 and has received consultancy fees from Merck Serono from 2008 to 2011.

Role of the funding source

The legal sponsor of the study was Merck KGaA, Darmstadt, Germany. The sponsor was responsible for data management and statistical analysis. The clinical study was designed in collaboration with the study coordinating investigator RS (EudraCT number 2006-002083-26). Editing of this manuscript was commissioned by the sponsor. The corresponding author (and all authors) had full access to all study data, and all

authors made the final decision to submit the manuscript for publication.

Acknowledgements

The authors would like to thank: Arnoud Templeton and Manuel Jungi, (both St. Gallen, Switzerland) for excellent help with patient care; Julia Rengier, (Lausanne, Switzerland) and Ruth Demmer, (St. Gallen, Switzerland) for meticulous study coordination and data management; Markus Jörgler (St. Gallen, Switzerland) for carefully reading the manuscript; Petra Pollert and Heike Pausch (Merck KGaA, Darmstadt, Germany) for operational study management, and assistance in medical data review; Regina Schick and Ky Trang (Merck KGaA, Darmstadt, Germany) for Drug Safety Surveillance. ICON Clinical Research (Dublin, Ireland) provided monitoring, data management and serious adverse event management. Analytical determination of PK was performed by Katja Parsche (Bureco AG, Reinach, Switzerland). Paul Hoban of Cancer Communications & Consultancy Ltd. (Knutsford, UK) provided medical writing services funded by Merck KGaA, Darmstadt, Germany.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.ejca.2012.07.015>.

References

- Davis CB, Gillies SD. Immunocytokines: amplification of anti-cancer immunity. *Cancer Immunol Immunother* 2003;**52**:297–308.
- Becker JC, Pancock JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. *J Exp Med* 1996;**183**(5):2361–6.
- Dolman CS, Mueller BM, Lode HN, Xiang R, Gillies SD, Reisfeld RA. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. *Clin Cancer Res* 1998;**4**(10):2551–7.
- Hank JA, Surfus JE, Gan J, et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). *Clin Cancer Res* 1996;**2**(12):1951–9.
- Grande C, Firvida JL, Navas V, Casal J. Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma. *Anticancer Drugs* 2006;**17**(1):1–12.
- Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 1999;**17**(7):2105–16.
- Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. *Cancer J Sci Am* 2000;**6**(Suppl. 1):S11–4.
- King DM, Albertini MR, Schalch H, et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. *J Clin Oncol* 2004;**22**(22):4463–73.

9. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. *Clin Cancer Res* 2006;**12**(6):1750–9.
10. Ko YJ, Bubley GJ, Weber R, et al. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer. *J Immunother* 2004;**27**(3):232–9.
11. Johannsen M, Spitaleri G, Curigliano G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. *Eur J Cancer* 2010;**46**(16):2926–35.
12. Sharifi J, Khawli LA, Hu P, King S, Epstein AL. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors. *Hybrid Hybridomics* 2001;**20**(5–6):305–12.
13. de Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. *Cancer Treat Rev* 2008;**34**(8):737–49.
14. Green DR. Apoptotic pathways: the roads to ruin. *Cell* 1998;**94**(6):695–8.
15. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. *Oncologist* 2006;**11**(4):342–57.
16. Proskuryakov SY, Gabai VL. Mechanisms of tumor cell necrosis. *Curr Pharm Des* 2010;**16**(1):56–68.
17. Chen S, Yu L, Jiang C, et al. Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. *J Clin Oncol* 2005;**23**(7):1538–47.
18. Shapiro WR, Carpenter SP, Roberts K, Shan JS. (131)I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. *Expert Opin Biol Ther* 2006;**6**(5):539–45.
19. Street HH, Goris ML, Fisher GA, et al. Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. *Cancer Biother Radiopharm* 2006;**21**(3):243–56.
20. Wang H, Cao C, Li B, et al. Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients. *Cancer Immunol Immunother* 2008;**57**(5):677–84.
21. Gillies SD, Lan Y, Hettmann T, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. *Clin Cancer Res* 2011;**17**(11):3673–85.
22. Gillies SD, Lo KM, Burger C, Lan Y, Dahl T, Wong WK. Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. *Clin Cancer Res* 2002;**8**(1):210–6.
23. Bass KK, Mastrangelo MJ. Immunopotential with low-dose cyclophosphamide in the active specific immunotherapy of cancer. *Cancer Immunol Immunother* 1998;**47**(1):1–12.
24. Ben-Efraim S. Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity. *Curr Drug Targets* 2001;**2**(2):197–212.
25. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. *Cancer Immunol Immunother* 2007;**56**(5):641–8.
26. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. *Blood* 2005;**105**(7):2862–8.
27. Abrams JS, Eiseman JL, Melink TJ, et al. Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial. *J Immunother Emphasis Tumor Immunol* 1993;**14**(1):56–64.
28. Ribas A, Kirkwood JM, Atkins MB, et al. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. *J Transl Med* 2009;**7**:68.
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;**92**(3):205–16.
30. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. *Nat Rev Immunol* 2008;**8**(1):59–73.
31. Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. *J Clin Oncol* 2010;**28**(33):4969–75.